Consonance Capital
Consonance Capital is a private equity firm based in New York that specializes in healthcare investments across various sectors, including providers, payors, pharmaceuticals, medical devices, and healthcare technology. Founded in 2005, the firm primarily targets lower middle market companies within the United States, focusing on growth equity, leveraged buyouts, and recapitalization transactions. Consonance Capital manages both public and private investments, with public equity operations directed by Consonance Capital Management and private investments managed by Consonance Capital Partners. The firm typically invests between $20 million and $45 million per transaction in companies with revenues ranging from $25 million to $500 million, emphasizing healthcare efficiency and innovation. In addition to direct investments, Consonance Capital also engages in fund of funds activities, collaborating with institutions and individuals to create client-focused equity portfolios.
Civic Eagle, Inc. provides a software solution designed for advocates and policy teams to efficiently manage legislative processes. Founded in 2015 and based in Minneapolis, Minnesota, the company offers a platform called Enview that consolidates state and federal bills with team communications. This platform allows lobbyists, policy professionals, and government affairs teams to discover, analyze, and track legislative developments without manual effort. By automating the discovery and management of legislation, Civic Eagle enables policy advocates to concentrate on their campaigns, ultimately promoting improved democratic outcomes for communities.
Surrozen, Inc. is a biopharmaceutical company based in South San Francisco, California, that specializes in developing targeted regenerative antibodies aimed at repairing tissues and organs affected by serious diseases. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate cell and organ-specific tissue regeneration. Its key programs include SZN-043, which is designed to promote hepatocyte regeneration in both acute and chronic liver diseases, and SZN-1326, an intestine-specific Wnt-mimetic intended to repair diseased epithelial tissue for patients suffering from inflammatory bowel disease. Surrozen was incorporated in 2015 and is focused on harnessing the body's self-renewal capabilities through precise control of the Wnt signaling pathway.
Silence Therapeutics is a biotechnology company based in the United Kingdom that specializes in the discovery and development of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company utilizes short interfering RNA (siRNA) technology to target and degrade specific messenger RNAs, thereby modulating gene expression. Its notable product candidates include SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to lower lipoprotein levels and reduce cardiovascular risks. Silence Therapeutics also engages in strategic collaborations, including a partnership with AstraZeneca to advance small interfering RNA therapeutics for multiple disease areas. Established as SR Pharma plc, the company rebranded to Silence Therapeutics in 2007 and is headquartered in London.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
Orsini Healthcare is a boutique, nationwide specialty pharmacy that focuses on programs for rare and complex medical conditions.
Psychiatric Medical Care is a mental health care company specializing in stress management services.
Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored for the hospice and palliative care sectors. Established in 1996 and based in Philadelphia, Pennsylvania, the company specializes in mail order pharmacy solutions and offers a range of services that include clinical support, medication dispensing systems, and hospice education resources. Enclara Pharmacia operates a direct-to-patient mail order model, facilitating the delivery of medications to patients' homes while also providing access to a network of retail and automated fulfillment pharmacies. By focusing on operational efficiency and value-based care, Enclara Pharmacia supports hospice providers in enhancing the quality of life for patients facing progressive illnesses. The company, formerly known as excelleRx, Inc., became a subsidiary of Eagle RX, Inc. in January 2020.
Since 1985, KEPRO has helped 20 million members lead healthier lives through clinical expertise, integrity and compassion. Our values are promises we keep every day. And why we keep growing with our clients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.